Article info

Download PDFPDF

Original research
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

Authors

  1. Correspondence to Philip J Mease; pmease{at}philipmease.com
View Full Text

Citation

Mease PJ, Gladman DD, Deodhar A, et al
Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

Publication history

  • Received March 2, 2020
  • Revision received May 1, 2020
  • Accepted May 6, 2020
  • First published July 13, 2020.
Online issue publication 
July 13, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.